LakeShore Biopharma Co Net Income

The latest net income for LSB is $-210M as of March 2024. That compares with $6.9M in the prior-year period — down 3182.5% year over year. That is below the sector sector average of $87M. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.

Over the past year, LSB's net income moved from $6.9M to $-210M — a 3182.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LakeShore Biopharma Co's operating scale or balance-sheet position.

Against its sector companies, LSB currently prints $-210M for net income, while the sector average sits near $87M. That is roughly 344.2% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co's growth, margins, and balance sheet.

A net income figure of $-210M for LSB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $87M. Explore the charts below for those layers of context.

After noting LSB's net income ($-210M), review year-over-year change from $6.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.